Allergy Therapeutics plc has disclosed a public dealing disclosure by an exempt principal trader, Panmure Gordon (UK) Limited, in accordance with Rule 8.5 of the Takeover Code. The disclosure relates to the trading activities of Panmure Gordon in relation to Allergy Therapeutics plc's relevant securities. The dealings were undertaken on September 11, 2023.

In terms of purchases and sales, Panmure Gordon purchased 28,815 securities of Allergy Therapeutics at a highest price per unit of 0.0282p and a lowest price per unit of 0.0282p. Additionally, Panmure Gordon made sales of 339,797 securities of Allergy Therapeutics at a highest price per unit of 0.0294p and a lowest price per unit of 0.0294p.

No cash-settled derivative transactions or stock-settled derivative transactions were reported in the disclosure.

The disclosure also states that there are no indemnity or option arrangements, agreements, or understandings relating to relevant securities that may be an inducement to deal or refrain from dealing.

Furthermore, there are no agreements, arrangements, or understandings relating to options or derivatives that affect the voting rights or future acquisition or disposal of any relevant securities.

The disclosure was made on September 12, 2023, and the contact person for further information is Lauren Riley, with a telephone number of 020 7886 2963.

Please note that this summary is based solely on the information provided in the news and does not include any additional information about Allergy Therapeutics plc or its operations.